Incheon City Takes off as Culture and Tourism Industry Hub in Northeast Asia with IFEZ’s Yeongjong Resort Complex Cluster
10.12.2019 15:00:00 EET | Business Wire | Press release
With rich tourism infrastructure and resources, including the world’s top-level Incheon International Airport, Ganghwa Island, open port area, and multiple islands, the Incheon Metropolitan City government plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005029/en/
Incheon City plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project. Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities. The first resort complex in Korea, the Paradise City comprises a 5-star hotel, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons opened in 2017. To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment. It will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool. Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment to open in 2022. (Photo: Business Wire)
Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities, such as luxurious 5-star hotels, foreigners-only casinos, convention installations, spas, theme parks and more.
Having opened in April 2017 as the first resort complex in Korea, the ‘Paradise City’ comprises a 5-star hotel with 711 rooms, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons. From September 2018, it has been operating a boutique hotel with 58 suite rooms, spa blended with Korean dry sauna culture, the largest recreation club in Northeast Asia, and an art exhibition space. In March 2019, it opened the Wonder Box, an indoor theme park with the concept of ‘amusement park in the evening’, presenting enjoyment both to foreign and local visitors.
To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment headquartered in Las Vegas. The Caesars Resort Complex will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool.
Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment (MGE), the owner of Mohegan Sun casino located in Connecticut, to open in 2022. The resort complex will include a luxury hotel with over 1,250 rooms, foreigners-only casino, and indoor and outdoor theme parks. It will also operate a performing facility (arena) that can accommodate 15,000 audiences, staging Las Vegas-level fantastic performances all year round. It is expected to significantly contribute to spreading the Korean Wave.
The Incheon Free Economic Zone Authority expects the resort complex businesses to generate over 20,000 new jobs and production inducement effect of approximately KRW2 trillion (USD1680 million) annually. It also expects that the resort complex industry will conspicuously contribute to invigorating the regional economy and development of the MICE industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005029/en/
Contact information
Incheon Metropolitan City
Sang Kon Park
+82 32-440-3052
sangkon7@korea.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom